http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TR-201709895-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_80bd2d2133175d39c9d62636f250a45f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-122 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-38 |
| filingDate | 2017-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b2507a8ea6e9faf6b5830ec5dd2b595 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19070941f4671880c68f1c523c9b7fd2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b522b583366a8dd0ed17151dd38b1c3 |
| publicationDate | 2019-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TR-201709895-A2 |
| titleOfInvention | The use of ferrugin a (fga) compound due to its biological activity as a chemotherapeutic agent and inhibitor of the mapk pathway. |
| abstract | The invention relates to the use of ferrugin A (FGA) compound, which exhibits an effective cytotoxic property in cancer chemotherapy, as an anticancer agent and inhibitor of the MAPK pathway. The object of the invention is the use of ferrugin A (FGA), a natural anthranoid that can be isolated from Harungana madagascariensis bark, as an anticancer agent and inhibitor of the MAPK pathway in MCF-7 cells. Within the scope of the invention, it is utilized that Ferrugin A has a low effect on human normal skin fibroblasts, thus selectively toxic to cancer cells. |
| priorityDate | 2017-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 21.